Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Dickerman, Barbra A.Torfadottir, Johanna E.
Valdimarsdottir, Unnur A.
Wilson, Kathryn M.
Steingrimsdottir, Laufey
Aspelund, Thor
Batista, Julie L.
Fall, Katja
Giovannucci, Edward
Sigurdardottir, Lara G.
Tryggvadottir, Laufey
Gudnason, Vilmundur
Markt, Sarah C.
Mucci, Lorelei A.
Issue Date
2018-03-15
Metadata
Show full item recordCitation
Midlife metabolic factors and prostate cancer risk in later life 2018, 142 (6):1166 International Journal of CancerAbstract
Metabolic syndrome is associated with several cancers, but evidence for aggressive prostate cancer is sparse. We prospectively investigated the influence of metabolic syndrome and its components on risk of total prostate cancer and measures of aggressive disease in a cohort of Icelandic men. Men in the Reykjavik Study (n = 9,097, enrolled 1967-1987) were followed for incident (n = 1,084 total; n = 378 advanced; n = 148 high-grade) and fatal (n = 340) prostate cancer until 2014. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for (1) measured metabolic factors at cohort entry (body mass index (BMI), blood pressure, triglycerides, fasting blood glucose) and (2) a metabolic syndrome score (range 0-4) combining the risk factors: BMI ≥30 kg/m2 ; systolic blood pressure (SBP) ≥130 or diastolic blood pressure (DBP) ≥85 mm Hg or taking antihypertensives; triglycerides ≥150 mg/dl; fasting blood glucose ≥100 mg/dl or self-reported type 2 diabetes. Hypertension and type 2 diabetes were associated with a higher risk of total, advanced, high-grade, and fatal prostate cancer, independent of BMI. Neither BMI nor triglycerides were associated with prostate cancer risk. Higher metabolic syndrome score (3-4 vs 0) was associated with a higher risk of fatal prostate cancer (HR 1.55; 95% CI: 0.89, 2.69; p trend = 0.08), although this finding was not statistically significant. Our findings suggest a positive association between midlife hypertension and diabetes and risk of total and aggressive prostate cancer. Further, metabolic syndrome as a combination of factors was associated with an increased risk of fatal prostate cancer.Description
To access publisher's full text version of this article click on the hyperlink belowAdditional Links
http://doi.wiley.com/10.1002/ijc.31142Rights
Archived with thanks to International Journal of Cancerae974a485f413a2113503eed53cd6c53
10.1002/ijc.31142
Scopus Count
Collections